In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Ezra Cohen, MD, FRCPSC, FASCO
Chief Medical Officer, Oncology
Tempus Labs
Professor of Medicine, Division of Hematology/Oncology
University of California San Diego Health
San Diego, CA, US
Consulting Fees: Adagene, Astellas, Cidara, Eisai, Genmab, Gilboa, iTeos, Lilly, MSD, Merck, Nectin Tx, Novartis, Nykode, Pangea Therapeutics, PCI Biotech, Replimune, Roche, Soteria, Tempus, Viracta
Employee of an ineligible company: Tempus Labs
Ownership Interest: Kinnate Biopharma, Primmune Therapeutics
Research: NCI
Faculty:
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Professor in Biological Cancer Therapies
The Institute of Cancer Research
London UK
Consulting Fees: AstraZeneca, Boehringer Ingelheim, Merck, MSD, Replimune
Research: AstraZeneca, Boehringer Ingelheim, Replimune
Deborah J. Wong, MD, PhD
Associate Clinical Professor of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA, US
Consulting Fees: MSD
Research: AstraZeneca, BICARA Therapeutics, Bristol-Myers Squibb Company, FSTAR Therapeutics, Genentech, Gilead, KURA Oncology, Lilly, MSD, Pfizer, Regeneron, TopAlliance
Reviewers/Content Planners/Authors:
- Jorge Bacigalupo has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose
- Robert Giest, MD, has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Tim Person has nothing to disclose.
- Rosanne Strauss PharmD, MBA, has nothing to disclose.